期刊
CLINICS IN PERINATOLOGY
卷 46, 期 2, 页码 291-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.clp.2019.02.011
关键词
Bronchopulmonary dysplasia; Chronic pulmonary insufficiency of prematurity; Pharmacology; Lungs
Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and post discharge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据